Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887872 | 0.91 | SLC6A2 (0.51) | USP30GPR119MEN1KMT2ASTS | |
| SCHEMBL5888078 | 0.89 | SLC6A2 (0.52) | USP30GPR119MEN1KMT2ASTS | |
| SCHEMBL5887980 | 0.88 | GPR119 (0.51) | USP30GPR119MEN1KMT2ASTS | |
| SCHEMBL4520405 | 0.85 | SLC6A2 (0.47) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4520408 | 0.85 | SLC6A2 (0.47) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5229717 | 0.82 | USP30 (0.53) | USP30GPR119MEN1KMT2A | |
| SCHEMBL5200971 | 0.82 | GPR119 (0.48) | USP30GPR119MEN1KMT2ASTS | |
| SCHEMBL5200443 | 0.81 | USP30 (0.52) | USP30GPR119MEN1KMT2A | |
| SCHEMBL5224399 | 0.81 | USP30 (0.52) | USP30GPR119MEN1KMT2A | |
| SCHEMBL13712551 | 0.81 | USP30 (0.47) | JAK2JAK1USP30GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | TPH1, TPH2, HTR1A | JAK2 2564/4885JAK1 3274/4885USP30 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.